Advertisement winmatch

Relief for Asthma Patients; AstraZeneca and Boehringer Ingelheim Cap Inhalers To Cost $35 a Month

Cap inhalers are a major component of asthma treatment primarily because their action is faster and they have fewer side effects than oral anti-asthmatic drugs.

However, asthma patients in the US are exacerbated by the high prices of inhalers, often many times that of inhalers in other countries.

The public outcry has led some drug makers to cap the cost of asthma inhalers at $35 a month.

Two of the most prominent manufacturers of cap inhalers, AstraZeneca and Boehringer Ingelheim, have reduced the price of cap inhalers to $35 a month, and the price reduction will come into effect from June 1.

AstraZeneca’s spokesperson has stated that insured and uninsured patients will be eligible for the $35 price cap.

He added that the price will be applicable for all of the inhalers the drugmaker sells in the U.S.

AstraZeneca chief executive Pascal Soriot said,

“AstraZeneca’s expanded savings programs build on our long-standing commitment to addressing barriers to access and affordability for patients living with respiratory diseases to ultimately help patients lead healthier lives.”

There are reports that another major pharma giant, GlaxoSmithKline, has also agreed to bring down the price of its cap inhalers to be on par with AstraZeneca and Boehringer Ingelheim.

The move is similar to the steps taken by insulin manufacturers last year following the passage of the Inflation Reduction Act.

As already mentioned, the price of cap inhalers is significantly higher in the U.S.

For example, AstraZeneca cap inhalers cost $645 in the U.S.

While they are available for $49 in the U.K.

Teva Pharmaceuticals cap inhalers are priced at $9 in Germany while they are available for $286 in the U.S.

The Democratic-led Senate Committee on Health, Education, Labor, and Pensions uncovered this fact.

Many asthma patients have said that despite having insurance, the cost of monthly treatment can skyrocket to $350 a month and is a big financial drain on the family’s income.

The high price tag of inhalers has also led to racial disparities, with asthma rates being slightly higher in Black Americans than in white Americans.

According to a report by the federal Office of Minority Health, Black children are 4.5 times more likely to be hospitalized for asthma compared to white children.

They are also 6 times more likely to die from asthma.

According to the Asthma and Allergy Foundation of America, 27 million people in the U.S. have asthma, including 5 million children.

Also Read: Joe Biden Administration Announces $7.7 Billion Student Loan Debt Relief, Know Who Are Eligible?

Manoj Nair

Manoj Nair: With a decade of news writing across various media platforms, Manoj is a seasoned professional. His dual role as an English teacher underscores his command over communication. He adeptly covers Politics, Technology, Crypto, and more, reflecting a broad and insightful perspective that engages and informs diverse audiences.

Related Articles